US regulator clears Biocon’s diabetic biosimilar product for Novolog
HQ Team July 15, 2025: The US Food and Drug Administration has approved a biosimilar product made by India’s Biocon Biologics Ltd., a.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 15, 2025: The US Food and Drug Administration has approved a biosimilar product made by India’s Biocon Biologics Ltd., a.
HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.
HQ Team June 11, 2025: Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an.
Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com